DEF: OS Therapies Schedules 2026 Annual Meeting

OS Therapies Incorporated announces its 2026 Annual Meeting of Stockholders, to be held virtually on September 9, 2026, with key proposals including director elections and incentive plan amendments.

Summary

• OS Therapies Incorporated is holding its 2026 Annual Meeting of Stockholders virtually on September 9, 2026, at 10:00 a.m. Eastern Time.
• Stockholders will vote on electing six directors, approving an amendment and restatement of the 2023 Incentive Compensation Plan, and ratifying the appointment of Malone Bailey, LLP as the independent registered public accounting firm for fiscal year 2026.
• The meeting will be accessible online, and stockholders of record as of July 21, 2026, are entitled to vote.
• The company is providing proxy materials electronically via a Notice of Internet Availability.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, as it primarily concerns routine corporate governance matters and does not contain significant financial performance updates or strategic shifts that would strongly influence sentiment.

Positives

• The company is holding its annual meeting to ensure continued corporate governance and stockholder engagement.
• The virtual meeting format is designed to facilitate stockholder attendance and participation from anywhere globally.
• The proposed amendment to the Incentive Compensation Plan aims to attract, motivate, and retain key personnel by increasing available shares and providing flexibility.
• The board of directors has determined that most directors are independent, enhancing oversight.

Negatives

• The company has not yet adopted a formal insider trading policy, relying on informal monitoring, though a formal policy is intended for adoption in 2026.
• Section 16(a) reports were filed late by all officers, directors, and greater than 10% stockholders for stock option award grants on October 21, 2025.

Risks

• The company faces risks as detailed in its Annual Report on Form 10-K, with management responsible for day-to-day risk management and the board for oversight.
• The proposed amendment to the Incentive Compensation Plan, if not approved, means the existing plan will remain in place.
• Failure to ratify the appointment of Malone Bailey, LLP could lead the Audit Committee to reconsider the firm.
• The company has not adopted a formal insider trading policy, which could pose a risk if not addressed.

Future Outlook

The company is seeking stockholder approval to amend and restate its 2023 Incentive Compensation Plan to increase the number of shares available for issuance by 5,000,000, eliminate per-person award limitations, and update provisions for tax law changes. This is intended to help attract, motivate, and retain executives and employees.

Management Comments

• "We have designed the format of the Annual Meeting to ensure that you are afforded the same rights and opportunities to participate as you would at an in-person meeting, using online tools to ensure your access and participation."
• "Our board of directors believes that the proposed increase in the number of shares available for issuance under the Amended and Restated Plan is necessary to enable us to attract, motivate, retain and reward executives and other employees, officers, directors, consultants and other persons who provide services to us through the use of competitive incentives that are tied to stockholder value."
• "Our board of directors believes that this is currently the appropriate leadership structure given the size and activities of the company."
• "Our board of directors has not adopted a formal insider trading policy governing the purchase, sale and/or other disposition of our securities by the Company, our directors, officers, employees and consultants that is reasonably designed to promote compliance with insider trading laws, rules and regulations, and any applicable NYSE American listing standards."

Industry Context

StockSavvy.ai notes that the proposed increase in share availability for the incentive compensation plan is a common strategy for biotechnology companies, especially those in clinical stages, to remain competitive in attracting and retaining talent in a high-demand sector.

Comparison to Industry Standards

• The proposed increase of 5,000,000 shares to the incentive compensation plan, bringing the total potential shares to 15,000,000, is a significant allocation for a company at this stage, reflecting the competitive nature of talent acquisition in the biotech industry.
• The company's reliance on equity-based compensation aligns with industry practices where cash conservation is prioritized, and long-term value creation is incentivized through stock ownership.
• The ratification of Malone Bailey, LLP as auditor is standard practice; the fees incurred ($302,625 in audit fees for 2025) are within a typical range for a company of this size and complexity, though direct industry benchmarks for audit fees are highly variable.
• The virtual meeting format is increasingly becoming an industry standard, adopted by many companies to improve accessibility and reduce costs.

Corporate Governance

Related Party Transactions

• Payroll advances to Paul A. Romness, CEO, totaling $134,184 were made during 2025 and fully repaid.
• Accounts payable to Shore Accountants MD Inc., owned by CFO Christopher P. Acevedo, were $0 as of December 31, 2025, down from $26,765 in 2024.

Stakeholder Impact

• Stockholders: Voting on director elections, incentive compensation plan, and auditor ratification directly impacts their influence and potential equity dilution.
• Employees: The proposed incentive compensation plan amendment could lead to increased equity awards, aligning their interests with stockholders.
• Management: Subject to director elections and compensation plan terms.
• Auditors: Malone Bailey, LLP's appointment is subject to stockholder ratification.

Next Steps

• Stockholders are to vote on the proposed resolutions at the Annual Meeting.
• The company will file a Current Report on Form 8-K with preliminary voting results within four business days following the Annual Meeting.
• Final voting results will be published in a subsequent Form 8-K filing.
• The company intends to adopt a formal insider trading policy during 2026.

Key Dates

Recommendation

This filing is a routine proxy statement for an annual meeting and does not contain new financial results, strategic shifts, or material events that would warrant a buy or sell recommendation. The proposals are standard corporate governance items, and the company's operational and financial status is best assessed through its periodic financial reports (10-K, 10-Q) rather than this procedural document.

Keywords

Annual Meeting, Proxy Statement, Director Election, Incentive Compensation Plan, Auditor Ratification, Virtual Meeting, Stockholder Proposals, Corporate Governance